Navigation Links
Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma
Date:6/4/2008

Results of phase I/II study highlighted in oral presentation at conference

on malignant lymphoma

LUGANO, Switzerland, June 5 /PRNewswire-FirstCall/ -- At the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland data were presented from a phase I/II investigator-sponsored clinical trial of Yttrium-90 Ibritumomab Tiuxetan (90Y-Zevalin) combined with the novel expanded porphyrin motexafin gadolinium (MGd). The greatest benefit of this investigational regimen was observed in rituximab-refractory follicular lymphoma patients, who experienced rapid responses and a high rate of durable complete responses (CR). In this subset of patients (n=14), 64 percent experienced a complete response with a median estimated time to progression (TTP) of 14 months. These results compare favorably to prior published data of single agent Zevalin in terms of CR and TTP. The investigators concluded that MGd given with Zevalin does not appear to increase hematologic or other toxicities. Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) markets Zevalin in the United States. MGd is under development by Pharmacyclics, Inc.

"Zevalin is approved for relapsed follicular non-Hodgkin's lymphoma based on superior overall and complete response rates compared to rituximab, including rituximab-refractory follicular non-Hodgkin's lymphoma where Zevalin resulted in a 74 percent overall response rate with 15 percent complete and unconfirmed complete responses," said James A. Bianco, M.D., President and CEO of CTI. "The results of the study suggest that addition of MGd may enhance the effectiveness of radioimmunotherapy with Zevalin. Further studies using this combination in patients with follicular or diffuse large B-cell lymphoma are warranted."

About the Study

Of the 30 patients enrolled on this study, 28 are currently evaluable. All patients were rituximab-refractory. No dose limiting toxicity was seen. No grade 4 non-he
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novel Technology Breaks Through Cancer Pain
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
4. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
5. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
6. NIST team develops novel method for nanostructured polymer thin films
7. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
8. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
9. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
10. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
11. GenVault and the National Center for Forensic Science to Present Novel Technology for Room Temperature Storage of RNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Pipette.com has ... to their comprehensive portfolio of Eppendorf products. , ... to purchase a Centrifuge 5424/5424 R and receive the ... either Eppendorf Research plus or Eppendorf Reference 2 ...
(Date:1/22/2015)... 22, 2015 Diagenode, Inc., a ... the Bioruptor® and complete solutions for epigenetics research, ... immunoprecipitation, alleviating the need for manual processing. The ... for ChIP of histones or transcription factors and ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... Wash. , Dec. 24, 2014   BioLife Solutions , ... and marketer of proprietary clinical grade hypothermic storage ... shipping products for cells and tissues  ("BioLife" or the ... Meeting of Stockholders on May 4, 2015 (the "Annual Meeting"). ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... /Xinhua-PRNewswire-FirstCall/ -- China,Pharma Holdings, Inc. ("China Pharma") ... markets generic and branded bio/pharmaceutical,products in China, ... LLP (SIG)"Beijing Management Summit" held in Beijing, ... September 2008., Attending this conference and ...
... September 1 , With some 20,000 UK ... the,new school year, new guidance from the National ... to revolutionise the way children,manage their diabetes, granting ... access to insulin pump therapy. The new,recommendations finally ...
... the electrical units of voltage, resistance and current ... nowadays used. Important prerequisites are extremely pure semiconductor ... without collision with residual impurities. To be prepared ... set up a new molecular beam epitaxy system ...
Cached Biology Technology:British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines 2British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines 3British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines 4'Racetrack' for fast electrons in semiconductor structures 2
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ...
(Date:12/10/2014)... 2014 You,ve been here before: you desperately need to sign ... key or the answer to your secret question. What,s your dog,s ... Hoyos Labs , a digital infrastructure security company, launches ... frustration that comes with usernames, passwords and PINs – 1U ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a new ... this $50 million capital project is part of a larger ... The medical education building will be located in ... to 525@vine in Wake Forest Innovation Quarter. Construction will begin ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Assistant Professor Frank J. Slack at Yale University has identified ... lung cancer, presenting new possibilities for diagnosis and treatment. The ... and Developmental Cell. , The oncogene Ras is out of ... over-expressed or activated by mutation. According to Slack, a member ...
... to block cat allergies successfully prevented allergic reactions in ... a test tube, University of California, Los Angeles (UCLA) ... available online now. In the future, the investigators say, ... not only for human cat allergies, but also possibly ...
... Researchers have created a way to transform the dead bone ... experiment involving mice. The advance, which uses gene therapy to ... bone, is a promising development for the thousands of cancer ... failing bone grafts. The findings were posted online Feb. 13 ...
Cached Biology News:Yale Scientists Find MicroRNA Regulates Ras Cancer Gene 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 3Gene therapy converts dead bone graft to new, living tissue 2Gene therapy converts dead bone graft to new, living tissue 3Gene therapy converts dead bone graft to new, living tissue 4
...
... a direct antibiotic-based selection system for recombinant ... survival, eliminating the need for costly color ... close to 100% accuracy in recombinant selection. ... robot colony picking. This cloning kit can ...
... direct antibiotic-based selection system for recombinant identification. ... eliminating the need for costly color screening. ... to 100% accuracy in recombinant selection. pLivSelect ... colony picking. This cloning kit can be ...
... PCR plate, Directly compatible with ABI thermal ... for improved sealing characteristics can be ... or cap strips, Certified free of DNase, ... part of Thermo Fisher Scientific, the world ...
Biology Products: